Most cancers-testing firm


Exact Sciences


hadn’t anticipated to report money income till this 12 months’s September quarter. However the vendor of the Cologuard check mentioned {that a} soar in December quarter gross sales helped delivered income forward of schedule.

Income rose 28% in 2022’s ultimate quarter to greater than $550 million, in keeping with preliminary numbers introduced by the Madison, Wis., firm on Sunday. Gross sales of screening merchandise just like the Cologuard stool check for colorectal most cancers jumped greater than 40%.